Focal adhesion kinase inhibitor TAE226 combined with Sorafenib slows down hepatocellular carcinoma by multiple epigenetic effects.
Romito I, Porru M, Braghini MR, Pompili L, Panera N, Crudele A, Gnani D, De Stefanis C, Scarsella M, Pomella S, Levi Mortera S, de Billy E, Conti AL, Marzano V, Putignani L, Vinciguerra M, Balsano C, Pastore A, Rota R, Tartaglia M, Leonetti C, Alisi A.
Romito I, et al. Among authors: marzano v.
J Exp Clin Cancer Res. 2021 Nov 16;40(1):364. doi: 10.1186/s13046-021-02154-8.
J Exp Clin Cancer Res. 2021.
PMID: 34784956
Free PMC article.